Merck’s Stock Jumps Over 5 Percent On Keytruda Trial Results

Merck (MRK) jumps over 5%

Shares of Merck (MRK) rose after positive results on trials of its Keytruda lung cancer drug.

This stock move has produced a large bullish candle that appears to confirm the multi-week reversal off the November lows. Question now becomes, “can active investors expect further upside?”

See our chart analysis of Merck’s stock and its market cycles below. There are two main things to highlight here:

1.  Note the bullish island reversal.

2.  Cycle patterns are suggesting new highs.

Merck (MRK) Weekly Stock Chart

Visit my site for more Cycle Analysis and Stock Picks.

Twitter:  @askslim

Any opinions expressed herein are solely those of the author, and do not in any way represent the views or opinions of any other person or entity.